Cleo Diagnostics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023
Other Revenue	2.56	0.85	0.21	-
Revenue	2.56	0.85	0.21	-
Revenue Growth (YoY)	1115.45%	300.91%	-	-
Gross Profit	2.56	0.85	0.21	-
Selling, General & Admin	2.48	1.88	1.1	1.37
Research & Development	3.8	2.88	2.57	0.25
Other Operating Expenses	0.1	0.1	0.12	0.04
Operating Expenses	6.44	4.93	3.85	1.7
Operating Income	-3.87	-4.08	-3.64	-1.7
Interest Expense	-	-	-0.03	-0.11
Interest & Investment Income	0.24	0.34	0.39	-
Other Non Operating Income (Expenses)	-0.4	-0.26	-0.48	0.08
Pretax Income	-4.03	-4	-3.76	-1.73
Net Income	-4.03	-4	-3.76	-1.73
Net Income to Common	-4.03	-4	-3.76	-1.73
Shares Outstanding (Basic)	129	129	117	26
Shares Outstanding (Diluted)	129	129	117	26
Shares Change (YoY)	10.54%	9.53%	346.76%	-
EPS (Basic)	-0.03	-0.03	-0.03	-0.07
EPS (Diluted)	-0.03	-0.03	-0.03	-0.07
Free Cash Flow	-2.52	-2.91	-2.03	-0.72
Free Cash Flow Per Share	-0.02	-0.02	-0.02	-0.03
Gross Margin	100.00%	100.00%	100.00%	-
Operating Margin	-151.15%	-483.01%	-1727.45%	-
Profit Margin	-157.36%	-473.17%	-1783.22%	-
Free Cash Flow Margin	-98.35%	-344.57%	-964.47%	-
EBITDA	-3.81	-4.02	-3.58	-1.66
D&A For EBITDA	0.06	0.06	0.06	0.04
EBIT	-3.87	-4.08	-3.64	-1.7

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.